NICE to reconsider evidence on interferon betaBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7271.1244/b (Published 18 November 2000) Cite this as: BMJ 2000;321:1244
- Roger Dobson
The National Institute for Clinical Excellence (NICE) is to reconsider the evidence for using interferon beta in the treatment of multiple sclerosis. The move follows an appeal against the provisional opinion of the appraisal committee of NICE that the drug had a modest clinical benefit outweighed by a high cost.
After the appeal hearing, the Multiple Sclerosis Society and Biogen, one of two drug makers who lodged appeals, said they were concerned about the length of time the evaluation had taken and the effects on patients. In its verdict, the NICE appeal panel said that the appraisal committee had not explained the basis …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial